MELISSA FERRELL: Open Payments
NPI 1427460187 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 20 payments from 10 companies in 2025. Trend: 2023 $881 · 2024 $619 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 2 | $145 |
| Novo Nordisk Inc | 4 | $145 |
| GENZYME CORPORATION | 3 | $88 |
| Regeneron Healthcare Solutions, Inc. | 2 | $65 |
| Lilly USA, LLC | 3 | $56 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $53 |
| Blueprint Medicines Corporation | 1 | $50 |
| Genentech USA, Inc. | 1 | $25 |
| Braeburn Inc. | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $14 |
Products named: DUPIXENT, SUBLOCADE, Ozempic, NEFFY, AYVAKIT, XOLAIR, ZEPBOUND, Wegovy.
Industry payments across AZ — which companies pay providers there.
